Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Post-authorisation Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto Rm) for the Prevention of Stroke in Patients with AF, Treatment of DVT and PE, and the Prevention of Recurrent DVT and PE in the Secondary Care Hospital Setting in England and Wales

Trial Profile

An Observational Post-authorisation Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto Rm) for the Prevention of Stroke in Patients with AF, Treatment of DVT and PE, and the Prevention of Recurrent DVT and PE in the Secondary Care Hospital Setting in England and Wales

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Aug 2018

At a glance

  • Drugs Rivaroxaban (Primary) ; Anticoagulants
  • Indications Deep vein thrombosis; Pulmonary embolism; Stroke
  • Focus Adverse reactions
  • Acronyms ROSE
  • Most Recent Events

    • 26 Aug 2018 Results (n=965) assessing starting dose amongst patients with chronic kidney stage 3 -4 or 5 presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
    • 26 Aug 2018 Results (n=965) presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
    • 26 Aug 2018 Results (n=2542) presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top